|
 |
European BioPharmaceutical Review
|
| The Emerging Enterprises Board of EuropaBio captures the essence of much of what EuropaBio is about as an agent of change and support for the issues that have a direct impact on the success of the European biotechnology sector. As Dr Philippe Pouletty, Chairman of this Board explains, "there are a number of major, broad measures which really need to be addressed if innovation, R&D-based industries (not just biotechnology) are to be competitive and deliver growth in Europe". |
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
Philippe Pouletty MD, is Vice-President of Europabio, President of France Biotech and the French Biotech Industry Association, and a General Partner of Truffle Venture, a new ¤150 million venture capital fund based in Paris, focusing on starting companies resulting from the spin-off of late stage technologies acquired from large companies or research institutes. He is the Founder of three biotechnology companies, a Board Member of several biotechnology companies and a limited Partner of several US and European venture capital funds. Founder and President of the recently created Strategic Council for Innovation, Dr Pouletty provides independent advice to the French government on innovation and research policy. He holds an MD degree from Paris V University, Immunology and Virology degrees from the Pasteur Institute, has been a post-doctoral research fellow at Stanford University, and was the 1999 laureate of the American Liver Foundation. He is a Chevalier de la Lйgion d'Honneur and the inventor of 20 patents in the health care and biotechnology fields. |
|
|
|
|
|
 |
Industry Events |
 |
Small Scale Biomanufacturing – clinical trials, cell & gene therapies
18 September 2008, Clifton Pavilion, Bristol Zoo Gardens, Bristol
This one day conference, sponsored by bioProcessUK and organised by BioApproaches South West, will cover key, important topics relating to small scale GMP biomanufacturing.
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Product Development Group, Inc
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today the addition of innovative state-of-the-art equipment at its formulation and manufacturing division, ApiCross Drug Delivery Technologies in Hollywood, Florida. The most recent acquisition is the MG Futura Capsule Filler which delivers the latest in capsule filling technology. The company has also added a Bausch & Strobel Aseptic Filling Isolator, equipment that is ground-breaking in the powder filling process. These additions support our previously implemented XcelodoseTM powder micro-dosing system. With these technologies, Azopharma is able to provide its clients with all forms of the capsule filling process. The new equipment is part of Azopharma’s recent manufacturing expansion which includes 17 new manufacturing suites for GMP, cytotoxic and aseptic products...
More info >> |
|
 |
